This double-blind study comparing interventional prospective study is to determine the effect of pioglitazone on blood glucose, inflammatory markers and oxidative stress in diabetic patients receiving insulin after renal transplantation on 60 patients with diabetes recently kidney transplants have been done.
The hospital's research center in Tehran will Labbafinejad martyr. The pioglitazone group will take the medication (30mg / d until glycemic control is achieved) and the second group will receive placebo for 4 months.
Incoming patients to the study, including patients with diabetes, which is one month before the transplant, renal function should be stable and should be treated with insulin.
Individuals with any history of having epidural early acute febrile and 30 ml / min GFR At baseline, hepatitis B, C, (New York Heart Association II-IV) CHF, pregnancy, received pulse corticosteroids, Acute rejection (disorder progressive renal an increase in creatinine mg / dl 1 and GFR drops below ml / min 30) 2 weeks before the study were excluded. The main objective of the study to achieve a fasting blood glucose 90-130 mg / dl and BS ≤ 160 mg / dl, and insulin dose will be calculated based on the. Intervals will visit patients every two weeks. Blood samples of 15 ml of venous blood to measure blood glucose levels, HbA1c, inflammatory markers: ESR, CRP, Faktvrhayaksydatyv stress: total protein carbonyls and malondialdehyde, IL-18 will be collected. The difference in the two groups during the medication is given.